CAPR · As filed with the SEC
Capricor Therapeutics income statement, by quarter
The statement as Capricor Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS · USD, except per-share amounts
| USD, except per-share amounts | Q2 2026 3 months ended Jun 30, 2026 | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024† 3 months ended Dec 31, 2024 | Q3 2024 3 months ended Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||
| TOTAL REVENUE | — | — | — | — | — | — | 11,130,509† | 2,261,642 |
| OPERATING EXPENSES | ||||||||
| Research and development | 28,866,292 | 27,376,912 | — | 20,359,098 | 22,047,254 | 18,915,572 | — | 11,807,867 |
| General and administrative | 14,079,328 | 9,395,941 | — | 5,924,942 | 5,671,880 | 6,067,376 | — | 3,463,655 |
| TOTAL OPERATING EXPENSES | 42,945,620 | 36,772,853 | — | 26,284,040 | 27,719,134 | 24,982,948 | — | 15,271,522 |
| LOSS FROM OPERATIONS | (42,945,620) | (36,772,853) | — | (26,284,040) | (27,719,134) | (24,982,948) | — | (13,009,880) |
| OTHER INCOME (EXPENSE) | ||||||||
| Other income (loss) | 2,271 | 8,145 | — | 6,740 | 14,991 | 12,485 | — | — |
| Investment income | 2,211,295 | 2,904,506 | — | 1,713,499 | 1,793,352 | 729,542 | — | 453,152 |
| Loss on disposal of fixed assets | — | (81,143) | — | (6,846) | — | (150,673) | — | — |
| TOTAL OTHER INCOME (EXPENSE) | 2,213,566 | 2,831,508 | — | 1,713,393 | 1,808,343 | 591,354 | — | 453,152 |
| LOSS BEFORE INCOME TAXES | (40,732,054) | (33,941,345) | — | — | — | — | — | — |
| (Provision for) benefit from income taxes | (1,600) | 0 | — | — | — | — | — | — |
| NET LOSS | (40,733,654) | (33,941,345) | — | (24,570,647) | (25,910,791) | (24,391,594) | — | (12,556,728) |
| OTHER COMPREHENSIVE INCOME (LOSS) | ||||||||
| Net unrealized gain (loss) on marketable securities | 90,186 | (536,881) | — | (543,452) | (424,353) | 784,972 | — | (58,766) |
| COMPREHENSIVE LOSS | (40,643,468) | (34,478,226) | — | (25,114,099) | (26,335,144) | (23,606,622) | — | (12,615,494) |
| Net loss per share, basic (in dollars per share) | (0.70) | (0.59) | — | (0.54) | (0.57) | (0.53) | — | (0.38) |
| Net loss per share, diluted (in dollars per share) | (0.70) | (0.59) | — | (0.54) | (0.57) | (0.53) | — | (0.38) |
| Weighted average number of shares, basic (in shares) | 57,926,347 | 57,434,267 | — | 45,716,151 | 45,709,071 | 45,636,633 | — | 33,090,063 |
| Weighted average number of shares, diluted (in shares) | 57,926,347 | 57,434,267 | — | 45,716,151 | 45,709,071 | 45,636,633 | — | 33,090,063 |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.